Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy

被引：2
|
作者：
Kyvsgaard, Emil R. [1 ,2 ,3 ]
Riley, Caroline [1 ,2 ]
Clausen, Michael Roost [4 ]
Harslof, Mads [1 ,2 ]
Heftdal, Line Dam [5 ]
Niemann, Carsten U. [1 ]
Gronbaek, Kirsten [1 ,2 ]
Hutchings, Martin [1 ,2 ]
Husby, Simon [1 ,2 ,3 ,6 ]
机构：
[1] Rigshosp, Dept Hematol, Copenhagen, Denmark
[2] Rigshosp, Phase 1 Unit, Copenhagen, Denmark
[3] Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, Copenhagen, Denmark
[4] Vejle Univ Hosp, Dept Hematol, Vejle, Denmark
[5] Rigshosp, Copenhagen Univ Hosp, Viroimmunol Res Unit, Dept Infect Dis, Copenhagen, Denmark
[6] Rigshosp, Dept Hematol, Gronbaek Grp, Ole Maaloes Vej 5, bygning 2, 3 Sal, DK-2200 Copenhagen N, Denmark
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 204卷 / 01期
关键词：
D O I：
10.1111/bjh.19156
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：356 / 360
页数：5
相关论文
共 50 条
  • [1] Low Mortality from COVID-19 Infection in Patients with B-Cell Lymphoma after Bispecific CD20xCD3 Therapy
    Kyvsgaard, Emil Ramso
    Riley, Anna Caroline Hasselbalch
    Clausen, Michael Roost
    Harslof, Mads
    Heftdal, Line Dam
    Niemann, Carsten Utoft
    Gronbaek, Kirsten
    Hutchings, Martin
    Husby, Simon
    BLOOD, 2023, 142
  • [2] NOTCH1 Mutations Are Associated With Therapy-Resistance in Patients With B-Cell Lymphoma Treated With CD20xCD3 Bispecific Antibodies
    Kyvsgaard, Emil R.
    Grauslund, Morten
    Sjo, Lene
    Melchior, Linea Cecilie
    Grantzau, Trine Lonbo
    Gjerdrum, Lise Mette Rahbek
    Trab, Trine
    Andersen, Laerke Sloth
    Gang, Anne Ortved
    Breinholt, Marie
    Moller, Michael Boe
    Christensen, Jacob Haaber
    Larsen, Thomas Stauffer
    Clausen, Michael Roost
    Riley, Caroline H.
    Niemann, Carsten U.
    Gronbaek, Kirsten
    Hutchings, Martin
    Husby, Simon
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (04) : 712 - 716
  • [3] CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma
    Ghobadi, Armin
    Bartlett, Nancy L.
    LANCET, 2021, 398 (10306): : 1109 - 1110
  • [4] CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL)- a Multicenter Retrospective Study
    Dong, Ning
    Khadka, Sushmita
    Sandoval-Sus, Jose
    Rondon, Carlos Silva
    Perez, Ariel
    Al Sagheer, Tiba
    Iqbal, Madiha
    Alderuccio, Juan Pablo
    Arocho, Cristian Rodriguez
    Kareem, Syeda Saba
    Jain, Michael D.
    Chavez, Julio C.
    BLOOD, 2024, 144 : 3091 - 3092
  • [5] IGM-2323 is a CD20xCD3 IgM bispecific T-cell engager that kills low CD20-expressing and rituximab-resistant B-cell lymphomas
    Li, K.
    Kotturi, M. F.
    Manlusoc, M.
    Yun, R.
    Hinton, P. R.
    Logronio, K.
    Baliga, R.
    Hernandez, G.
    Sinclair, A. M.
    Carroll, S. F.
    Godfrey, W. R.
    Keyt, B. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S778 - S779
  • [6] Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20xCD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Matasar, Matthew
    Tucker, David
    Kim, Tae Min
    Luminari, Stefano
    Cheng, Yuan
    Li, Jingjin
    Shariff, Saleem
    Mohamed, Hesham
    Ambati, Srikanth
    Chaudhry, Aafia
    BLOOD, 2024, 144 : 3076 - 3077
  • [7] Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting
    Sun, Hao
    Xing, Haizhou
    Han, Lijie
    Song, Yongping
    Jiang, Zhongxing
    Liu, Yanyan
    Yu, Jifeng
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (05) : 321 - 326
  • [8] Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20xCD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
    Brouwer-Visser, Jurriaan
    Fiaschi, Nathalie
    Deering, Raquel P.
    Cygan, Kamil J.
    Scott, Darius
    Jeong, Se
    Boucher, Lauren
    Gupta, Namita T.
    Gupta, Suraj
    Adler, Christina
    Topp, Max S.
    Bannerji, Rajat
    Duell, Johannes
    Advani, Ranjana H.
    Flink, Dina M.
    Chaudhry, Aafia
    Thurston, Gavin
    Ambati, Srikanth R.
    Jankovic, Vladimir
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
  • [9] Tafasitamab in Combination with a CD20xCD3 Bispecific T-Cell Engager Significantly Prolongs Survival in Preclinical Lymphoma Models
    Schaadt, Eveline
    Heitmueller, Christina
    Peters, Solveig
    Ilieva, Kristina
    Blair, Derek
    Huth, Christiane
    Bartel, Dominik
    Zapf, Sandra
    Eberl, Markus
    Mangelberger-Eberl, Doris
    Giles, Frank
    Corvey, Carsten
    BLOOD, 2023, 142
  • [10] COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma
    Gaitzsch, Erik
    Passerini, Verena
    Khatamzas, Elham
    Strobl, Carolin D.
    Muenchhoff, Maximilian
    Scherer, Clemens
    Osterman, Andreas
    Heide, Michael
    Reischer, Anna
    Subklewe, Marion
    Leutbecher, Alexandra
    Tast, Benjamin
    Ruhle, Adrian
    Weiglein, Tobias
    Stecher, Stephanie-Susanne
    Stemmler, Hans J.
    Dreyling, Martin
    Girl, Philipp
    Georgi, Enrico
    Woelfel, Roman
    Mateyka, Laura
    D'Ippolito, Elvira
    Schober, Kilian
    Busch, Dirk H.
    Kager, Juliane
    Spinner, Christoph D.
    Treiber, Matthias
    Rasch, Sebastian
    Lahmer, Tobias
    Iakoubov, Roman
    Schneider, Jochen
    Protzer, Ulrike
    Winter, Christof
    Ruland, Juergen
    Quante, Michael
    Keppler, Oliver T.
    von Bergwelt-Baildon, Michael
    Hellmuth, Johannes
    Weigert, Oliver
    HEMASPHERE, 2021, 5 (07): : E603
12345